These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 30502114)

  • 21. Aptamer delivery of siRNA, radiopharmaceutics and chemotherapy agents in cancer.
    de Almeida CEB; Alves LN; Rocha HF; Cabral-Neto JB; Missailidis S
    Int J Pharm; 2017 Jun; 525(2):334-342. PubMed ID: 28373101
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assays for aptamer-based platforms.
    Citartan M; Gopinath SC; Tominaga J; Tan SC; Tang TH
    Biosens Bioelectron; 2012 Apr; 34(1):1-11. PubMed ID: 22326894
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recent Methods for Purification and Structure Determination of Oligonucleotides.
    Zhang Q; Lv H; Wang L; Chen M; Li F; Liang C; Yu Y; Jiang F; Lu A; Zhang G
    Int J Mol Sci; 2016 Dec; 17(12):. PubMed ID: 27999357
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The development and testing of aptamers for cancer.
    Barbas AS; White RR
    Curr Opin Investig Drugs; 2009 Jun; 10(6):572-8. PubMed ID: 19513946
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Applications of aptamers in targeted imaging: state of the art.
    Dougherty CA; Cai W; Hong H
    Curr Top Med Chem; 2015; 15(12):1138-52. PubMed ID: 25866268
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Radiolabeling of Nucleic Acid Aptamers for Highly Sensitive Disease-Specific Molecular Imaging.
    Hassanzadeh L; Chen S; Veedu RN
    Pharmaceuticals (Basel); 2018 Oct; 11(4):. PubMed ID: 30326601
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Investigations on the interface of nucleic acid aptamers and binding targets.
    Cai S; Yan J; Xiong H; Liu Y; Peng D; Liu Z
    Analyst; 2018 Nov; 143(22):5317-5338. PubMed ID: 30357118
    [TBL] [Abstract][Full Text] [Related]  

  • 28. NOTA and NODAGA [
    Makris G; Radford LL; Kuchuk M; Gallazzi F; Jurisson SS; Smith CJ; Hennkens HM
    Bioconjug Chem; 2018 Dec; 29(12):4040-4049. PubMed ID: 30412382
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aptamers in the Therapeutics and Diagnostics Pipelines.
    Kaur H; Bruno JG; Kumar A; Sharma TK
    Theranostics; 2018; 8(15):4016-4032. PubMed ID: 30128033
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Promising Scandium Radionuclides for Nuclear Medicine: A Review on the Production and Chemistry up to In Vivo Proofs of Concept.
    Huclier-Markai S; Alliot C; Kerdjoudj R; Mougin-Degraef M; Chouin N; Haddad F
    Cancer Biother Radiopharm; 2018 Oct; 33(8):316-329. PubMed ID: 30265573
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Single amino acid chelates (SAAC): a strategy for the design of technetium and rhenium radiopharmaceuticals.
    Bartholomä M; Valliant J; Maresca KP; Babich J; Zubieta J
    Chem Commun (Camb); 2009 Feb; (5):493-512. PubMed ID: 19283279
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nucleic acid-based aptamers: applications, development and clinical trials.
    Kanwar JR; Roy K; Maremanda NG; Subramanian K; Veedu RN; Bawa R; Kanwar RK
    Curr Med Chem; 2015; 22(21):2539-57. PubMed ID: 25723512
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PET imaging of tenascin-C with a radiolabeled single-stranded DNA aptamer.
    Jacobson O; Yan X; Niu G; Weiss ID; Ma Y; Szajek LP; Shen B; Kiesewetter DO; Chen X
    J Nucl Med; 2015 Apr; 56(4):616-21. PubMed ID: 25698784
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chelating systems for (99m)Tc/(188)Re in the development of radiolabeled peptide pharmaceuticals.
    Bolzati C; Carta D; Salvarese N; Refosco F
    Anticancer Agents Med Chem; 2012 Jun; 12(5):428-61. PubMed ID: 22292757
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development and application of peptide-based radiopharmaceuticals.
    Dijkgraaf I; Boerman OC; Oyen WJ; Corstens FH; Gotthardt M
    Anticancer Agents Med Chem; 2007 Sep; 7(5):543-51. PubMed ID: 17896914
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Aptamers: Potential Diagnostic and Therapeutic Agents for Blood Diseases.
    Aljohani MM; Cialla-May D; Popp J; Chinnappan R; Al-Kattan K; Zourob M
    Molecules; 2022 Jan; 27(2):. PubMed ID: 35056696
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Increasing the Net Negative Charge by Replacement of DOTA Chelator with DOTAGA Improves the Biodistribution of Radiolabeled Second-Generation Synthetic Affibody Molecules.
    Westerlund K; Honarvar H; Norrström E; Strand J; Mitran B; Orlova A; Eriksson Karlström A; Tolmachev V
    Mol Pharm; 2016 May; 13(5):1668-78. PubMed ID: 27010700
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nucleic acid aptamers in diagnosis of colorectal cancer.
    Ahmadyousefi Y; Malih S; Mirzaee Y; Saidijam M
    Biochimie; 2019 Jan; 156():1-11. PubMed ID: 30244135
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Aptamer chemistry.
    Röthlisberger P; Hollenstein M
    Adv Drug Deliv Rev; 2018 Sep; 134():3-21. PubMed ID: 29626546
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Update: aptamers as novel radiopharmaceuticals: their applications and future prospects in diagnosis and therapy.
    Missailidis S; Perkins A
    Cancer Biother Radiopharm; 2007 Aug; 22(4):453-68. PubMed ID: 17803440
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.